FGF2 and pancreatic neoplasm: Compared with the bFGF-treated control group, a dose-dependent decrease in the migration of Panc01 and Panc02 cells was observed as the concentration of rAj-HRP30 increased, further confirming that rAj-HRP30 inhibits the migratory ability of pancreatic cancer cells in a concentration-dependent manner.